EUVIMEDEUVIMED entdecken
Crossref

RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic regulation of CD4 + T helper cell differentiation during non-small cell lung cancer (NSCLC)

Roshni Bibi, Melvin George, Koustav Sarkar

Medical Oncology · 27.12.2025 · 43 (2)

DOI: 10.1007/s12032-025-03230-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, online erschienen am 27.12.2025. Verfasst von Roshni Bibi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, 603203, India. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Epigenesis, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Ministry of Tribal Affairs, Govt. of India, Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The accurate control of immune responses in the tumor microenvironment is crucial for augmenting anti-cancer immunity. This work examined the function of STAT3 in modulating epigenetic and epitranscriptomic pathways during the differentiation of CD4 + T helper cells in non-small cell lung cancer (NSCLC). Employing CRISPR/Cas9 genome editing, STAT3 was specifically eliminated in CD4+T cells derived from NSCLC patients. Functional investigations demonstrated that the reduction of STAT3 markedly enhanced the production of T helper 1 (TH1) cytokines, notably IFN-γ, while concurrently diminishing immunosuppressive signaling. Epigenetic analysis revealed significant modifications in DNA and RNA methylation patterns, along with heightened R-loop formation-alterations linked to augmented transcriptional activity of anti-tumor immune genes. Moreover, STAT3-deficient CD4+T cells demonstrated an enhanced ability to activate cytotoxic T lymphocytes, facilitating the targeted eradication of tumor cells. All of these effects together made the NSCLC microenvironment's immune system better at fighting cancer. Our results identify STAT3 as a crucial regulator of the genetic and epigenetic frameworks that influence T cell functionality in lung cancer. By combining RNA-guided genome editing with immune functional tests, we show that blocking STAT3 in a specific way could bring back strong anti-tumor immunity. This research underscores the therapeutic potential of STAT3-targeted therapies, presenting an innovative approach to alter T cell destiny and improve immune-mediated tumor eradication in non-small cell lung cancer (NSCLC). These methods could lead to the next generation of immunotherapies that improve clinical outcomes by fine-tuning both epigenetic and epitranscriptomic circuits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorCarcinoma, Non-Small-Cell LungLung NeoplasmsEpigenesis, GeneticCD4-Positive T-LymphocytesHumansCell DifferentiationTumor MicroenvironmentDNA MethylationGene Expression Regulation, NeoplasticCRISPR-Cas SystemsTranscriptome

Stichwörter der Autor:innen

CD4⁺T helper cellsCRISPR/Cas9Epigenetic regulationM6A RNA methylationSTAT3

Substanzen

STAT3 Transcription FactorSTAT3 protein, human

Autor:innen und Institutionen

  • Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, 603203, India.
  • Centre for Clinical Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Chennai, Tamil Nadu, 603203, India.
  • Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, 603203, India. koustavm@srmist.edu.in.

Förderung

  • Ministry of Tribal Affairs, Govt. of India
  • Indian Council of Medical Research

Zitieren

APA

Bibi, R., George, M., & Sarkar, K. (2025). RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic regulation of CD4 + T helper cell differentiation during non-small cell lung cancer (NSCLC). Medical Oncology, 43(2). https://doi.org/10.1007/s12032-025-03230-1

Vancouver

Bibi R, George M, Sarkar K. RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic regulation of CD4 + T helper cell differentiation during non-small cell lung cancer (NSCLC). Medical Oncology. 2025;43(2). doi:10.1007/s12032-025-03230-1

BibTeX
@article{Bibi2025,
  author = {Bibi, Roshni and George, Melvin and Sarkar, Koustav},
  title = {RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic regulation of CD4 + T helper cell differentiation during non-small cell lung cancer (NSCLC)},
  journal = {Medical Oncology},
  year = {2025},
  volume = {43},
  number = {2},
  doi = {10.1007/s12032-025-03230-1}
}
Kostenlos starten →